Page 4 - Risk Evaluation News Today

The future of medication abortion access in the United States went in front of the U.S. Supreme Court justices on Tuesday, where several justices appeared somewhat skeptical as anti-abortion organizations argued use of the pharmaceutical should be moved back to what was in place before 2016.

The abortion and miscarriage care drug mifepristone is at the center of a case being heard by the U.S. Supreme Court that seeks to limit access to it. Here is a history of the drug and what's happening now that the Supreme Court has overturned national abortion rights.

BioPharma

Merck shares posted the biggest rise in the Dow Jones index on Wednesday, reaching an all-time high after US health authorities gave the go-ahead for the prescription of its Winrevair to treat...

The Supreme Court’s opinion on the case will likely arrive sometime early this summer.

A timeline provides key dates in the history of mifepristone, from its 1980 development to ongoing Supreme Court arguments.

Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients.

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

The American Academy of Dermatology issued updated guidelines for the management of acne in adults, adolescents, and preadolescents.

Life News